Invitation to submit a proposal by direct award for the acquisition of O4 - OCTREOTIDE [0.1 MG/1ML; F/AMP]

This tender is an invitation for proposals via a direct award process for the acquisition of a specific pharmaceutical product: Octreotide, with a dosage of 0.1 mg/1ml, supplied in an ampoule (F/AMP). A direct award process typically means that the procuring entity has identified a specific supplier or has specific reasons for not conducting a full open tender, often due to urgency, specialization, or existing contracts. Octreotide is a synthetic analogue of the hormone somatostatin, used to treat conditions such as acromegaly, carcinoid syndrome, and certain types of tumors. The tender specifies the exact formulation and packaging required. The objective is to procure this essential medication efficiently. Suppliers capable of providing this specific Octreotide formulation are invited to submit their proposals according to the terms outlined by the procuring entity.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 2,349.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.